ARCHIVES

FDA Advisors Give Dox-SL Conditional Approval; Ok Zoladex

This article is from The Cancer Letter archive.

Vol. 21 No. 08 | February 24, 1995

Download PDF Visit The Full Archive

Related Articles

Advocacy: Friends To Continue Another Year

June 13, 1997

AACR, ASCO Publish Reports Examining U.S. Cancer Care

April 4, 2014

Phase III Regorafenib Trial Meets Endpoint Improving Progression-Free Survival

April 27, 2012

Proposed FDA Charges For NDA Drugs, Biologics Submissions Would Total $76 Million In FY 1990

January 27, 1989

CCOPs Get $1 Million More, Payline Raised To 228 Plus Exceptions

May 29, 1987

NCI-Approved Clinical Trials

December 31, 2004